Spectrum Of Activity
Candidemia, disseminated candidiasisEsophageal candidiasis200 mg IV 1 dose, then 100 mg IV q24h x≥14d after the last positive culture100 mg IV 1 dose, then 50 mg IV q24h x≥14dNo renal dose adjustment
Safety and effectiveness in pediatric patients ≤16y of age have not been established
No dose adjustment
Candidiasis of the esophagus
Candidiasis of the esophagus - HIV infection
Invasive candidiasis, Intra-abdominal and peritonitis
Prior to initiation, obtain specimens for fungal culture and other relevant laboratory studies (including histopathology).
Improvement in signs and symptoms of fungal infection is indicative of efficacy.
Monitor hepatic function during therapy.
Deep venous thrombosis
Abnormal liver function
No significant interactions
Antimicrobial class: Antifungal, Echinocandins, Glucans Synthesis Inhibitor
Pregnancy category: B
Average serum half life: 26.5 hours
Urine penetration: Therapeutic
Monitoring recommended for liver function test abnormalities.
Discontinue use if anaphylactic reactions occur.
Risk of metabolic crisis in patients with hereditary fructose intolerance (HFI). Obtain history of HFI symptoms with exposure prior to treatment.